-
Mashup Score: 150th Year of Publication: Progress in Rheumatology During the 2010s - 6 month(s) ago
In this edition of The Journal of Rheumatology , I will be bringing to your attention the following 6 articles from the 2010s that had, and continue to have, a significant impact in rheumatology. Although I usually choose 3 papers, I have chosen 6 that can be grouped into 3 categories. The first category has a single paper that describes a modification of the American College of Rheumatology (ACR) classification of fibromyalgia (FM),1 the second category contains 2 papers on the use of the internet and social media in rheumatology,2,3 and the third contains 3 papers on long-term outcome studies in rheumatoid arthritis (RA).4-6 The first paper I wish to bring to your attention is “Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia” by Wolfe et al. … Address correspondence to Dr. E.D. Silverman, Editor-in-Chief, The Journal of Rheumatology, 365 Bloor Street East, Suite 901, Toronto
Source: www.jrheum.orgCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial - 9 month(s) ago
Xinlei Ma and co-workers investigate tofacitinib as a possible treatment for patients with polymyalgia rheumatica.
Source: journals.plos.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Tocilizumab Biosimilar CT-P47 Demonstrates Pharmacokinetic Equivalence - 10 month(s) ago
All primary endpoints evaluating pharmacokinetics were achieved and immunogenicity and safety were comparable across treatment arms.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study - 11 month(s) ago
Objective To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis. Methods Patients who had an inadequate response to methotrexate (MTX) with or without biological disease-modifying antirheumatic drugs were randomly divided into two groups at baseline, and tofacitinib treatment in combination with MTX was administered to both groups….
Source: RMD OpenCategories: Latest Headlines, RheumatologyTweet-
open-label randomised study in #RA patients and inadequate #MTX response receiving #tofacitinib addon -48/113 in remission at week 52 then stop either tofa or MTX At week 104: 7/24 with tofa stop remain remission 10/20 with MTX stop remain in remission https://t.co/AgI6oUyWnn https://t.co/qAITxuB6T2
-
-
Mashup Score: 0Tofacitinib-Treated Women With PsA Less Likely to Achieve MDA - 12 month(s) ago
At month 3, patients treated with tofacitinib achieved higher rates of ACR20/50, MDA, and PASI75 in both sexes when compared with the placebo. However, female patients were less likely to achieve MDA when compared with males.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Compared with other bDMARDs, patients with rheumatoid arthritis treated with tofacitinib had a 4-fold reduced incidence of interstitial lung disease.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Patients with psoriatic arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive tofacitinib, according to data published in BMC Rheumatology. “Dactylitis is considered a core domain of musculoskeletal symptoms in PsA and is important for both patients and physicians when developing treatment strategies,”
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Patients with psoriatic arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive tofacitinib, according to data published in BMC Rheumatology. “Dactylitis is considered a core domain of musculoskeletal symptoms in PsA and is important for both patients and physicians when developing treatment strategies,”
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Objective The efficacy of tofacitinib (TOF) in the early diagnosis of melanoma differentiation–associated gene 5 (MDA5)–related interstitial lung disease (ILD) has been described. However, whether TOF exposure is associated with a reduced 1-year mortality rate remains undetermined. Methods Patients diagnosed with MDA5-ILD receiving TOF or tacrolimus (TAC) treatment were included. A Cox…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1‘No clear increased risk’ for CV events with tofacitinib in ORAL Surveillance post-hoc - 1 year(s) ago
PHILADELPHIA — There is “no clear increased risk” for major adverse cardiovascular events associated with tofacitinib, according to a post-hoc analysis of the ORAL Surveillance trial presented at ACR Convergence 2022.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
50th Volume Reprint Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies 📰 https://t.co/WlKRndLtfO #tofacitinib #rheumatoidarthritis https://t.co/xQ8DBs69id